Microfluidic technologies have recently been applied as innovative methods for the production of a variety of nanomedicines (NMeds), demonstrating their potential on a global scale. The capacity to precisely control variables, such as the flow rate ratio, temperature, total flow rate, etc., allows for greater tunability of the NMed systems that are more standardized and automated than the ones obtained by well-known benchtop protocols. However, it is a crucial aspect to be able to obtain NMeds with the same characteristics of the previously optimized ones. In this study, we focused on the transfer of a production protocol for hybrid NMeds (H-NMeds) consisting of PLGA, Cholesterol, and Pluronic® F68 from a benchtop nanoprecipitation method to a microfluidic device. For this aim, we modified parameters such as the flow rate ratio, the concentration of core materials in the organic phase, and the ratio between PLGA and Cholesterol in the feeding organic phase. Outputs analysed were the chemico–physical properties, such as size, PDI, and surface charge, the composition in terms of %Cholesterol and residual %Pluronic® F68, their stability to lyophilization, and the morphology via atomic force and electron microscopy. On the basis of the results, even if microfluidic technology is one of the unique procedures to obtain industrial production of NMeds, we demonstrated that the translation from a benchtop method to a microfluidic one is not a simple transfer of already established parameters, with several variables to be taken into account and to be optimized.

Microfluidic technology for the production of hybrid nanomedicines / Ottonelli, I.; Duskey, J. T.; Rinaldi, A.; Grazioli, M. V.; Parmeggiani, I.; Vandelli, M. A.; Wang, L. Z.; Prud'Homme, R. K.; Tosi, G.; Ruozi, B.. - In: PHARMACEUTICS. - ISSN 1999-4923. - 13:9(2021), pp. 1495-1495. [10.3390/pharmaceutics13091495]

Microfluidic technology for the production of hybrid nanomedicines

Ottonelli I.;Duskey J. T.;Rinaldi A.;Grazioli M. V.;Parmeggiani I.;Vandelli M. A.;Tosi G.;Ruozi B.
2021

Abstract

Microfluidic technologies have recently been applied as innovative methods for the production of a variety of nanomedicines (NMeds), demonstrating their potential on a global scale. The capacity to precisely control variables, such as the flow rate ratio, temperature, total flow rate, etc., allows for greater tunability of the NMed systems that are more standardized and automated than the ones obtained by well-known benchtop protocols. However, it is a crucial aspect to be able to obtain NMeds with the same characteristics of the previously optimized ones. In this study, we focused on the transfer of a production protocol for hybrid NMeds (H-NMeds) consisting of PLGA, Cholesterol, and Pluronic® F68 from a benchtop nanoprecipitation method to a microfluidic device. For this aim, we modified parameters such as the flow rate ratio, the concentration of core materials in the organic phase, and the ratio between PLGA and Cholesterol in the feeding organic phase. Outputs analysed were the chemico–physical properties, such as size, PDI, and surface charge, the composition in terms of %Cholesterol and residual %Pluronic® F68, their stability to lyophilization, and the morphology via atomic force and electron microscopy. On the basis of the results, even if microfluidic technology is one of the unique procedures to obtain industrial production of NMeds, we demonstrated that the translation from a benchtop method to a microfluidic one is not a simple transfer of already established parameters, with several variables to be taken into account and to be optimized.
13
9
1495
1495
Microfluidic technology for the production of hybrid nanomedicines / Ottonelli, I.; Duskey, J. T.; Rinaldi, A.; Grazioli, M. V.; Parmeggiani, I.; Vandelli, M. A.; Wang, L. Z.; Prud'Homme, R. K.; Tosi, G.; Ruozi, B.. - In: PHARMACEUTICS. - ISSN 1999-4923. - 13:9(2021), pp. 1495-1495. [10.3390/pharmaceutics13091495]
Ottonelli, I.; Duskey, J. T.; Rinaldi, A.; Grazioli, M. V.; Parmeggiani, I.; Vandelli, M. A.; Wang, L. Z.; Prud'Homme, R. K.; Tosi, G.; Ruozi, B.
File in questo prodotto:
File Dimensione Formato  
pharmaceutics-13-01495-v2 (1).pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 1.74 MB
Formato Adobe PDF
1.74 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1253777
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 1
social impact